Pardes Biosciences Valuation
| PRDSDelisted Stock | USD 2.14 0.01 0.47% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Pardes Biosciences holds a recent Real Value of $1.75 per share. The prevailing price of the company is $2.14. Our model determines the value of Pardes Biosciences from analyzing the company fundamentals such as Shares Owned By Institutions of 72.05 %, shares outstanding of 62.01 M, and Return On Equity of -0.4 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Pardes Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Pardes Biosciences is based on 3 months time horizon. Increasing Pardes Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pardes stock is determined by what a typical buyer is willing to pay for full or partial control of Pardes Biosciences. Since Pardes Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pardes Stock. However, Pardes Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.14 | Real 1.75 | Hype 2.14 |
The intrinsic value of Pardes Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pardes Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pardes Biosciences helps investors to forecast how Pardes stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pardes Biosciences more accurately as focusing exclusively on Pardes Biosciences' fundamentals will not take into account other important factors: Pardes Biosciences Total Value Analysis
Pardes Biosciences is at this time forecasted to have valuation of (22.1 M) with market capitalization of 133.95 M, debt of , and cash on hands of 228.6 M. The negative valuation of Pardes Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pardes Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(22.1 M) | 133.95 M | 228.6 M |
Pardes Biosciences Asset Utilization
One of the ways to look at asset utilization of Pardes is to check how much profit was generated for every dollar of assets it reports. Pardes Biosciences holds a negative application of assets of -0.26 pct., losing $0.002649 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Pardes Biosciences shows how discouraging it operates for each dollar spent on its assets.Pardes Biosciences Ownership Allocation
Pardes Biosciences owns a total of 62.01 Million outstanding shares. The majority of Pardes Biosciences outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pardes Biosciences to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pardes Biosciences. Please pay attention to any change in the institutional holdings of Pardes Biosciences as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pardes Biosciences Profitability Analysis
Net Loss for the year was (96.63 M) with profit before overhead, payroll, taxes, and interest of 0.About Pardes Biosciences Valuation
The delisted stock valuation mechanism determines Pardes Biosciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pardes Biosciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pardes Biosciences. We calculate exposure to Pardes Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pardes Biosciences's related companies.Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. The company was incorporated in 2020 and is headquartered in Carlsbad, California. Pardes Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 61 people.
Pardes Biosciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pardes Biosciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 58.1 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Pardes Stock
If you are still planning to invest in Pardes Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Pardes Biosciences' history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |